Aurinia Pharmaceuticals Inc. (AUPH) Stock Profile — Insider Trades & Financials

Revenue$77.1M

Net Income$210.8M

EPS$2.07

Market Cap$2.1B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Kevin Tang

CEO & Executive Director

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Founded: 1993
Employees: 128
Headquarters: Edmonton, AB T5L 4S6, Canada
Website

⚡

Core Efficiency

ROE?

36.26%

ROA?

28.05%

D/E Ratio?

0.29

Op. Margin?

43.10%

📊

Profitability Ratios

Net Margin?

273.35%

Loading company sections...

Aurinia Pharmaceuticals Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness